Brief: Tourmaline Bio Initiates Clinical Development Of TOUR006 For Cardiovascular Diseases
16/05/2024 12:13
May 16 (Reuters) - Tourmaline Bio Inc TRML.O :
* TOURMALINE BIO INITIATES CLINICAL DEVELOPMENT OF TOUR006
FOR
CARDIOVASCULAR DISEASES WITH FIRST PATIENT DOSED IN PHASE 2
TRANQUILITY TRIAL
* TOURMALINE BIO INC: TOPLINE DATA ANTICIPATED IN FIRST HALF
OF
2025
Source text for Eikon: ID:nGNXbNS8q4
Further company coverage: TRML.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tourmaline Bio
See all newsBrief: Novartis Completes Acquisition Of Tourmaline Bio
Brief: Novartis Announces Expiration Of Tourmaline Bio Tender Offer
Novartis nears deal to acquire Avidity Biosciences for over $70 per share, Bloomberg News reports (updated)
Brief: Novartis Announces Commencement Of Tender Offer To Acquire Tourmaline Bio
U.S. STOCKS ON THE MOVE-Potbelly, Joby, Talen Energy